The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Cited by
Sorted by citations
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,419
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,972
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,612
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,583
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,506
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Mortality in COPD: role of comorbidities
Sin, D. D., Anthonisen, N. R., Soriano, J. B., & Agusti, A. G. (2006) · European Respiratory Journal · doi:10.1183/09031936.00133805 · Cited by 1,052
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 968
Jemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Ward, E., Wu, X., Eheman, C. R., Anderson, R. N., Ajani, U. A., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 961
Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L., Golzarian, J., Gornik, H. L., Halperin, J. L., Jaff, M. R., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.023 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluentialFihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737
Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 729
O’Donnell, D. E., Aaron, S. D., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M. S., Ford, G. T., Gervais, A., Goldstein, R. S., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 658
Greenfield, S. F., Back, S. E., Lawson, K., & Brady, K. T. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.01.004 · Cited by 602
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Weight gain in smokers after quitting cigarettes: meta-analysis
Aubin, H.-J., Farley, A., Lycett, D., Lahmek, P., & Aveyard, P. (2012) · BMJ · doi:10.1136/bmj.e4439 · Cited by 510
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
Wu, P., Wilson, K., Dimoulas, P., & Mills, E. J. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-300 · Cited by 484
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies
Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2013) · Circulation · doi:10.1161/circulationaha.113.003961 · Cited by 413
Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400
Qaseem, A., Fihn, S. D., Williams, S., Dallas, P., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00010 · Cited by 391
Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390
Steensland, P., Simms, J. A., Holgate, J. Y., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 368
Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease
Rigotti, N. A., Pipe, A., Benowitz, N. L., Arteaga, C., Garza, D., & Tonstad, S. (2010) · Circulation · doi:10.1161/circulationaha.109.869008 · Cited by 368
Smoking and Chronic Obstructive Pulmonary Disease (COPD). Parallel Epidemics of the 21st Century
Laniado-Laborı́n, R. (2009) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph6010209 · Cited by 380
Gender and Chronic Obstructive Pulmonary Disease
Han, M. K., Postma, D. S., Mannino, D. M., Giardino, N. D., Buist, S. A., Curtis, J. L., & Martínez, F. J. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200704-553cc · Cited by 358
The relevance and treatment of cue-induced cravings in tobacco dependence
Ferguson, S. G., & Shiffman, S. S. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.06.005 · Cited by 366
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann‐Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 357
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318212bb8b · Cited by 352
Aubin, H.-J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008) · Thorax · doi:10.1136/thx.2007.090647 · Cited by 344
Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L., Golzarian, J., Gornik, H. L., Halperin, J. L., Jaff, M. R., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31822e80c3 · Cited by 339
Interventions for preventing weight gain after smoking cessation
Farley, A., Hájek, P., Lycett, D., & Aveyard, P. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 340
Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg, M. J., Filion, K. B., Yavin, D., Bélisle, P., Mottillo, S., Joseph, L., Gervais, A., O’Loughlin, J. L., Paradis, G., Rinfret, S., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070256 · Cited by 316
Lerman, C. E., Schnoll, R. A., Hawk, L. W., Cinciripini, P. M., George, T. P., Wileyto, E. P., Swan, G. E., Benowitz, N. L., Heitjan, D. F., & Tyndale, R. F. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70294-2 · Cited by 302
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee, S. A., Harrison, E. L. R., O’Malley, S. S., Krishnan‐Sarin, S., Shi, J. M., Tetrault, J. M., Picciotto, M. R., Petrakis, I. L., Estevez, N., & Balchunas, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.029 · Cited by 307
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.028 · Cited by 282
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 275
Leone, F. T., Zhang, Y., Evers‐Casey, S., Evins, A. E., Eakin, M. N., Fathi, J. T., Fennig, K., Folan, P. A., Galiatsatos, P., Gogineni, H. P., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-1982st · Cited by 267
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Tønnesen, P., Carrozzi, L., Fagerström, K. O., Gratziou, C., Jimenez-Ruiz, C. A., Nardini, S. G., Viegi, G., Lazzaro, C. R., Campell, I. A., Dagli, E., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00060806 · Cited by 252
Zangen, A., Moshe, H., Martinez, D., Barnea‐Ygael, N., Vapnik, T., Bystritsky, A., Duffy, W., Toder, D., Casuto, L., Grosz, M. L., et al. (2021) · World Psychiatry · doi:10.1002/wps.20905 · Cited by 247
Gepner, A. D., Piper, M. E., Johnson, H. M., Fiore, M. C., Baker, T. B., & Stein, J. H. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.09.023 · Cited by 249
The Past, Present, and Future of Nicotine Addiction Therapy
Prochaska, J. J., & Benowitz, N. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-033712 · Cited by 245
Smoking cessation during substance abuse treatment: What you need to know
Baca, C. T., & Yahne, C. E. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.06.003 · Cited by 228
Hatsukami, D. K., Stead, L. F., & Gupta, P. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60871-5 · Cited by 227
Varenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222
Hollis, J. F., McAfee, T. A., Fellows, J. L., Zbikowski, S. M., Stark, M., & Riedlinger, K. (2007) · Tobacco Control · doi:10.1136/tc.2006.019794 · Cited by 220
Healthcare financing systems for increasing the use of tobacco dependence treatment
van den Brand, F. A., Nagelhout, G. E., Reda, A. A., Winkens, B., Evers, S., Kotz, D., & van Schayck, O. C. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004305.pub5 · Cited by 217
Supporting smoking cessation: a guide for health professionals.
Zwar, N. A., RICHMOND, R. L., Borland, R., Peters, M. J., Litt, J., Bell, J., Caldwell, B., & Ferretter, I. T. (2012) · Cited by 215
Rooke, T. W., Hirsch, A. T., Misra, S., Sidawy, A. N., Beckman, J. A., Findeiss, L., Golzarian, J., Gornik, H. L., Halperin, J. L., Jaff, M. R., et al. (2011) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2011.09.001 · Cited by 212
Effect of Varenicline on Smoking Cessation Through Smoking Reduction
Ebbert, J. O., Hughes, J. R., West, R., Rennard, S. I., Russ, C., McRae, T. D., Treadow, J., Yu, C., Dutro, M. P., & Park, P. W. (2015) · JAMA · doi:10.1001/jama.2015.280 · Cited by 215
Effects of Varenicline on Smoking Cessation in Patients With Mild to Moderate COPD
Tashkin, D. P., Rennard, S. I., Hays, J. T., Ma, W., Lawrence, D., & Lee, T. C. (2010) · CHEST Journal · doi:10.1378/chest.10-0865 · Cited by 209
Stapleton, J., Watson, L. A., Spirling, L. I., Smith, R. C., Milbrandt, A., Ratcliffe, M., & Sutherland, G. (2007) · Addiction · doi:10.1111/j.1360-0443.2007.02083.x · Cited by 206
West, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1041-3 · Cited by 203
Armstrong, E. J., Wu, J., Singh, G. D., Dawson, D. L., Pevec, W. C., Amsterdam, E. A., & Laird, J. R. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.08.064 · Cited by 202
Prochaska, J. J., & Hilton, J. F. (2012) · BMJ · doi:10.1136/bmj.e2856 · Cited by 202
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Cappelleri, J. C., Zou, K. H., Bushmakin, A. G., Alvir, J. M. J., Alemayehu, D., & Symonds, T. L. (2013) · Chapman & Hall/CRC eBooks · doi:10.1201/b16139 · Cited by 198
Treating Smokers in the Health Care Setting
Fiore, M. C., & Baker, T. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1101512 · Cited by 196
Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders
McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W., & Gray, K. M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0142-x · Cited by 200
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 201
Effects of Nicotine in Experimental Animals and Humans: An Update on Addictive Properties
Foll, B. L., & Goldberg, S. R. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_12 · Cited by 200
Effects of Smoking and Smoking Cessation on Endothelial Function
Johnson, H. M., Gossett, L. K., Piper, M. E., Aeschlimann, S. E., Korcarz, C. E., Baker, T. B., Fiore, M. C., & Stein, J. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.002 · Cited by 196
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub5 · Cited by 187
Interventions for smokeless tobacco use cessation
Ebbert, J. O., Elrashidi, M. Y., & Stead, L. F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004306.pub5 · Cited by 186
Nakamura, M., Oshima, A., Fujimoto, Y., Maruyama, N., Ishibashi, T., & Reeves, K. R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.012 · Cited by 185
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1932-6 · Cited by 191
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.185752 · Cited by 185
Managing tobacco use: the neglected cardiovascular disease risk factor
Rigotti, N. A., & Clair, C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht352 · Cited by 190
Smoking Cessation: An Integral Part of Lung Cancer Treatment
Cataldo, J. K., Dubey, S., & Prochaska, J. J. (2010) · Oncology · doi:10.1159/000319937 · Cited by 181
Tønnesen, P. (2013) · European Respiratory Review · doi:10.1183/09059180.00007212 · Cited by 181
Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 181
Abuse Liability Assessment of Tobacco Products Including Potential Reduced Exposure Products
Carter, L. P., Stitzer, M. L., Henningfield, J. E., O'Connor, R. J., Cummings, K. M., & Hatsukami, D. K. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0948 · Cited by 186
Diaz, F. J., James, D., Botts, S., Maw, L., Susce, M. T., & De Leon, J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00664.x · Cited by 179
Varenicline decreases alcohol consumption in heavy-drinking smokers
Mitchell, J., Teague, C. H., Kayser, A. S., Bartlett, S. E., & Fields, H. L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2717-x · Cited by 179
Rational Development of Addiction Pharmacotherapies: Successes, Failures, and ProspectsPreprint
Pierce, R. C., O'Brien, C. P., Kenny, P. J., & Vanderschuren, L. J. M. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a012880 · Cited by 178
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Fagerström, K., Russ, C., Yu, C.-R., Yunis, C., & Foulds, J. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts018 · Cited by 175
Tobacco addiction and the dysregulation of brain stress systems
Bruijnzeel, A. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.02.015 · Cited by 181
Koegelenberg, C. F. N., Noor, F., Bateman, E. D., van Zyl-Smit, R. N., Bruning, A., O’Brien, J., Smith, C., Abdool-Gaffar, M. S., Emanuel, S., Esterhuizen, T. M., et al. (2014) · JAMA · doi:10.1001/jama.2014.7195 · Cited by 172
New Methods for Tobacco Dependence Treatment Research
Baker, T. B., Mermelstein, R. J., Collins, L. M., Piper, M. E., Jorenby, D. E., Smith, S. S., Christiansen, B. A., Schlam, T. R., Cook, J. W., & Fiore, M. C. (2010) · Annals of Behavioral Medicine · doi:10.1007/s12160-010-9252-y · Cited by 170
Strategies to Help a Smoker Who Is Struggling to Quit
Rigotti, N. A. (2012) · JAMA · doi:10.1001/jama.2012.13043 · Cited by 169
Mills, E. J., Wu, P., Lockhart, I., Thorlund, K., Puhan, M. A., & Ebbert, J. O. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.705016 · Cited by 163
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
Louie, S., Zeki, A. A., Schivo, M., Chan, A. L., Yoneda, K. Y., Avdalovic, M. V., Morrissey, B. M., & Albertson, T. E. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.2 · Cited by 161
How Can We Use Our Knowledge of Alcohol-Tobacco Interactions to Reduce Alcohol Use?
McKee, S. A., & Weinberger, A. H. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185549 · Cited by 164
Thomas, K. H., Martin, R. M., Knipe, D. W., Higgins, J. P. T., & Gunnell, D. (2015) · BMJ · doi:10.1136/bmj.h1109 · Cited by 155
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
